{"id":55584,"date":"2023-04-06T14:04:22","date_gmt":"2023-04-06T12:04:22","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/psychogenics-launches-ecube-a-new-ai-enabled-platform-for-drug-discovery\/"},"modified":"2023-04-06T14:04:22","modified_gmt":"2023-04-06T12:04:22","slug":"psychogenics-launches-ecube-a-new-ai-enabled-platform-for-drug-discovery","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/psychogenics-launches-ecube-a-new-ai-enabled-platform-for-drug-discovery\/","title":{"rendered":"PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery"},"content":{"rendered":"
\n

\neCube Harnesses Machine Learning to Identify CNS Compounds and Predict Their Therapeutic Applications for Neuropsychiatric Disorders<\/i><\/p>\n

PARAMUS, N.J.–(BUSINESS WIRE)–PsychoGenics Inc.<\/a> (\u201cPsychoGenics\u201d or the \u201cCompany\u201d), a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, announced today that it has launched eCube\u00ae, a novel pharmaco-electroencephalography (\u201cpharmacoEEG\u201d) platform to support phenotypic drug discovery, which unlike traditional target-based drug discovery, can identify novel treatments with multiple targets. Similar to the Company’s AI-enabled, behavior-based platform, SmartCube\u00ae, eCube harnesses machine learning to identify CNS penetrant compounds and predict their therapeutic applications for neuropsychiatric disorders by comparing their EEG profiles to an extensive pharmacoEEG database comprised of hundreds of doses of CNS-active reference drugs.<\/p>\n

\neCube measures drug-induced changes to EEG spectra data and utilizes machine learning classifiers trained on reference drugs to predict the efficacy of novel compounds at the drug class (primary therapeutic indication) and subclass (primary mechanism of action) levels. In addition to predicting therapeutic applications for novel compounds, eCube can deliver translational biomarkers, providing an objective way to assess CNS activity, which is particularly important for compounds with unknown or complex mechanisms of action.<\/p>\n

\n\u201cThe eCube platform joins PsychoGenics\u2019 innovative class of AI-enabled phenotypic platforms, including SmartCube, which has helped advance numerous compounds to clinical trials, including Ulotaront. Discovered in partnership with Sunovion, Ulotaront is now in Phase 3 for schizophrenia, as well as depression and generalized anxiety disorder,\u201d said Emer Leahy, Ph.D., CEO, PsychoGenics. \u201ceCube is another important discovery tool helping bring novel treatments to patients suffering from severely disabling conditions.\u201d<\/p>\n

\n\u201cThe introduction of eCube provides a truly unique translational tool for target-agnostic compound screening and lead generation. Our reference EEG databases and analytical machine learning tools not only allow us to predict therapeutic efficacy, but also to quantify the similarity of EEG spectra to other CNS drugs,\u201d added Dani Brunner, Ph.D., Chief Innovation Officer, PsychoGenics. \u201cThis powerful platform can confirm the therapeutic predictions from our behavior-based platforms, identify neuronal circuitry and provide translational biomarkers to support clinical development.\u201d<\/p>\n

\nAbout PsychoGenics<\/b><\/p>\n

\nPsychoGenics Inc. and its discovery arm, PGI Drug Discovery LLC (collectively known as PsychoGenics), have pioneered the translation of rodent behavioral and physiological responses into robust, high-throughput and high-content phenotyping. PsychoGenics\u2019 drug discovery platforms SmartCube\u00ae, NeuroCube\u00ae, and PhenoCube\u00ae have been used in shared-risk partnerships with major pharmaceutical companies, including Sunovion, Roche and Karuna, resulting in the discovery of several novel compounds now in clinical trials or advanced preclinical development. PsychoGenics\u2019 capabilities also include standard behavioral testing, electrophysiology, translational EEG, molecular biology, microdialysis and quantitative immunohistochemistry, and, now, eCube(\u2122). In addition, the Company offers a variety of in-licensed transgenic mouse models that support research in areas such as Huntington\u2019s disease, autism spectrum disorders, psychosis\/schizophrenia, depression, PTSD, Alzheimer\u2019s disease, Parkinson\u2019s disease, muscular dystrophy, ALS and seizure disorders. For more information, visit PsychoGenics.com<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contacts<\/b>
McKenna Miller \/ Shana Marino
\n
KCSA Strategic Communications
\n
949.606.6585 \/ 347.487.6189<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

eCube Harnesses Machine Learning to Identify CNS Compounds and Predict Their Therapeutic Applications for Neuropsychiatric Disorders PARAMUS, N.J.–(BUSINESS WIRE)–PsychoGenics Inc. (\u201cPsychoGenics\u201d or the \u201cCompany\u201d), a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, announced today that it has launched eCube\u00ae, a novel pharmaco-electroencephalography (\u201cpharmacoEEG\u201d) platform to support phenotypic drug discovery, which unlike traditional … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55584","6":"format-standard","7":"category-industry"},"yoast_head":"\nPsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/psychogenics-launches-ecube-a-new-ai-enabled-platform-for-drug-discovery\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"eCube Harnesses Machine Learning to Identify CNS Compounds and Predict Their Therapeutic Applications for Neuropsychiatric Disorders PARAMUS, N.J.–(BUSINESS WIRE)–PsychoGenics Inc. (\u201cPsychoGenics\u201d or the \u201cCompany\u201d), a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, announced today that it has launched eCube\u00ae, a novel pharmaco-electroencephalography (\u201cpharmacoEEG\u201d) platform to support phenotypic drug discovery, which unlike traditional ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/psychogenics-launches-ecube-a-new-ai-enabled-platform-for-drug-discovery\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-06T12:04:22+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-launches-ecube-a-new-ai-enabled-platform-for-drug-discovery\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-launches-ecube-a-new-ai-enabled-platform-for-drug-discovery\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery\",\"datePublished\":\"2023-04-06T12:04:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-launches-ecube-a-new-ai-enabled-platform-for-drug-discovery\\\/\"},\"wordCount\":491,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-launches-ecube-a-new-ai-enabled-platform-for-drug-discovery\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-launches-ecube-a-new-ai-enabled-platform-for-drug-discovery\\\/\",\"name\":\"PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2023-04-06T12:04:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-launches-ecube-a-new-ai-enabled-platform-for-drug-discovery\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-launches-ecube-a-new-ai-enabled-platform-for-drug-discovery\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/psychogenics-launches-ecube-a-new-ai-enabled-platform-for-drug-discovery\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/psychogenics-launches-ecube-a-new-ai-enabled-platform-for-drug-discovery\/","og_locale":"en_US","og_type":"article","og_title":"PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery - Pharma Trend","og_description":"eCube Harnesses Machine Learning to Identify CNS Compounds and Predict Their Therapeutic Applications for Neuropsychiatric Disorders PARAMUS, N.J.–(BUSINESS WIRE)–PsychoGenics Inc. (\u201cPsychoGenics\u201d or the \u201cCompany\u201d), a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, announced today that it has launched eCube\u00ae, a novel pharmaco-electroencephalography (\u201cpharmacoEEG\u201d) platform to support phenotypic drug discovery, which unlike traditional ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/psychogenics-launches-ecube-a-new-ai-enabled-platform-for-drug-discovery\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-06T12:04:22+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/psychogenics-launches-ecube-a-new-ai-enabled-platform-for-drug-discovery\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/psychogenics-launches-ecube-a-new-ai-enabled-platform-for-drug-discovery\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery","datePublished":"2023-04-06T12:04:22+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/psychogenics-launches-ecube-a-new-ai-enabled-platform-for-drug-discovery\/"},"wordCount":491,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/psychogenics-launches-ecube-a-new-ai-enabled-platform-for-drug-discovery\/","url":"https:\/\/pharma-trend.com\/en\/psychogenics-launches-ecube-a-new-ai-enabled-platform-for-drug-discovery\/","name":"PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2023-04-06T12:04:22+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/psychogenics-launches-ecube-a-new-ai-enabled-platform-for-drug-discovery\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/psychogenics-launches-ecube-a-new-ai-enabled-platform-for-drug-discovery\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/psychogenics-launches-ecube-a-new-ai-enabled-platform-for-drug-discovery\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55584","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55584"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55584\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55584"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55584"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55584"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}